الفهرس 
Liver cirrhosisOnly 14 pages are availabe for public view
 |  | from | 156 |  |  |
| | | from | 156 | | |
Abstract
Hepatocellular carcinoma (HCC) is a major cause of morbidity
and mortality; it is the sixth most common cancer world-wide, and the
third leading cause of cancer related deaths. Its prognosis is poor and
early detection is of great importance.
Alpha-fetoprotein (AFP) is the currently available traditional
marker for the detection of hepatocellular carcinoma. Its poor
sensitivity renders it unsatisfactory for this purpose and suggests an
urgent need for novel biomarkers for early stage HCC detection.
LTBP-1 is identified cytoplasmic protein partner of integrins that
is important component of focal adhesion complexes of adherent
cells.LTBP-1 has been identified as a novel molecular marker for HCC
progression and has revealed that its up regulation is associated with
HCC progression showing that it may serve as a prognostic marker.
The present study directed towards evaluation the role of serum
LTBP-1 as a novel biomarker for the diagnosis of HCC and comparison
between this marker and the traditional marker AFP.
This study was conducted in Clinical Pathology Department,
National Liver Institute, Menoufia University.
The study included 90 subjects classified into three groups.
group (I): included 30 patients with liver cirrhosis, (23) males and (7)
females. group (II): included 40 patients with hepatocellular carcinoma
as diagnosed by triphasic CT, (29) males and (11) females. group (III):
Included 20 apparently healthy volunteers age and gender matched
with the diseased groups served as control, (19) males and (1) females.